+1.224.938.9523

HUMAN AMYLOID IMAGING CONFERENCE

The 2021 edition of the conference has been cancelled. We look forward to seeing you in 2022!

HAI 2020 POSTER SESSIONS


Click the “+” to open each module; tables can be sorted by clicking on each item of the header row (board number, poster title, authors and presenter, respectively).  Additionally, each table is searchable (use the search field located at the top right of each module).

Please note that we reserve the right to re-arrange the poster allocation.  

POSTER SESSIONS: 1A - Wednesday, January 15 - 9:45 - 10:30 am; 1B - Wednesday, January 15, 4:00 - 4:45 pm
BOARDTitleAuthor NamePresenter
1Label-free x-ray method for estimating brain amyloid loadBadano | Dahal | GhammraouiBadano
29Application of an epidemic spreading model to characterize amyloid beta accumulation in dutosomal dominant Alzheimer’s disease mutation carriersLevitis | Vogel | Kiar | Funck | Iturria-Medina | EvansLevitis
12Voxel-wise relationships between white matter hyperintensities (WMH) and multimodal neuroimaging biomarkers of Alzheimer’s diseaseGaubert | Lange | Garnier-Crussard | Bougacha | Gonneaud | de Flores | Tomadesso | Mézenge | Landeau | de La Sayette | Chételat | WirthLange
46PET imaging of [11C]MPC-6827, a micrtoubule-based PET tracer in murine models of Alzheimer's diseaseSolingapuram sai | Macauley | Whitlow | Mintz | CraftSolingapuram sai
4A pons cluster detected by a data-driven approach may serve as a favorable reference region for 18F-PI-2620 Tau PET analysisBischof | van Eimeren | Koglin | Müller | Bullich | Perrotin | Stephens | DrzezgaBischof
11Influence of iron and beta-amyloid deposition on entorhinal cortex and hippocampal subfield volumes in the aging brainFoster | Kennedy | RodrigueFoster
17[11C]PiB amyloid quantification and choice of reference regionHeeman | Hendriks | van Berckel | Lopes Alves | Lammertsma | YaqubHeeman
47Quantifying the relationship between the brain distributions of tau and local atrophy to inter-regional connectivity based on individual human dataSoucy | Mohammadi | Rosa-Neto | Pascoal | Savard | Kang | Therriault | BenaliSoucy
52PET beta-amyloid deposition in healthy older adults is associated with decreased lure discrimination on a spatial mnemonic similarity taskWebb | Foster | Horn | Kennedy | RodrigueWebb
21Concordance of visual and quantitative assessments of baseline amyloid scans in the GRADUATE gantenerumab studiesKlein | Delmar | Voyle | Hesterman | Petrulli | Ovens | Baudler | Fontoura | Doody | KerchnerKlein
54Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s diseaseWolters | Visser | Verfaillie | Coomans | Timmers | Tuncel | Boellaard | Windhorst | Scheltens | van der Flier | Ossenkoppele | van BerckelWolters
53Socioeconomic status mediates racial differences seen using the A-T(N) FrameworkWisch | Hudson | Coble | Xiong | Babulal | Gordon | Flores | Dincer | Benzinger | Morris | AncesAnces
27Probability Template Method for Analysis of Down Syndrome Amyloid PETLaymon | Minhas | James | Christian | Cohen | Klunk | Tudorascu | Royse | Zaman | HandenLaymon
36Association between Cerebral Amyloid Accumulation and Synaptic Density in Alzheimer’s Disease: A Multitracer PET StudyO Dell | Mecca | Chen | Godek | Harris | Bartlett | Banks | Kominek | Zhao | Naganawa | Toyonaga | Lu | Nabulsi | Vander Wyk | Varma | Arnsten | Huang | Carson | van DyckO'Dell
10Quantifying off-target skull binding in [18F]Flortaucipir PET studiesFlores | Gordon | Su | Christensen | Dincer | Adedokun | Hornbeck | Morris | BenzingerFlores
40MIND MAPS: Assessment of the mitochondrial - endoplasmic reticulum - synaptic axis in neurodegeneration by [18F]BCPP-EF, [11C]SA4503 and [11C]UCB-J PET imagingRabiner | Mansur | Venkataraman | Price | Wilson | Pagano | Clarke | Lewis | Matthews | Rowe | Brooks | Middleton | Politis | Rohrer | Comley | Evans | Martarello | Chen | Schwarz | Schmidt | Tsukada | Passchier | Gunn | ConsortiumRabiner
14Amyloid binding is associated with markers of white matter microstructure in patients with significant white matter diseaseGoubran | Ozzoude | Adamo | Zukotynski | Bocti | Borrie | Chertkow | Frayne | Gao | Hsiung | Kiss | Laforce | Noseworthy | Prato | Ramirez | Sahlas | Scott | Smith | Sossi | Strother | Swartz | Tardif | Thiel | Soucy | BlackGoubran
20Hippocampal volume mediates the relationship between amyloidosis and amyloid-sensitive cognitive composite in preclinical ADKim | Hahn | Kim | Kim | Chin | SeoHahn
7Tau pathology and synaptic loss are closely associated in Alzheimer’s disease in vivo: a combined [18F]flortaucipir and [11C]UCB-J PET studyCoomans | Verfaillie | Wolters | Tuncel | Golla | Ossenkoppele | Scheper | Schober | Sweeney | Ryan | Schuit | Windhorst | Scheltens | Boellaard | van BerckelCoomans
5Early detection of amyloid load using 18F-Florbetaben PETBullich | Roé-Vellvé | Marquié | Villemagne | Sanabria | Tartari | Sotolongo | Doré | Koglin | Müller | Perrotin | De Santi | Tárraga | Stephens | Rowe | Seibyl | BoadaBullich
8Longitudinal dynamic [18F]flortaucipir PET reveals increased early stage tau pathology in individuals with subjective cognitive declineCoomans | Visser | Ossenkoppele | Verfaillie | Timmers | Wolters | Tuncel | Schmidt | Boellaard | Windhorst | Scheltens | van der Flier | van BerckelCoomans
34Sex-specific differences in [18F]AV-1451 off-target retentionMinhas | Yu | Laymon | Lopresti | Snitz | Tudorascu | Aizenstein | Lopez | Mathis | Klunk | CohenMinhas
33MRI and PET data harmonization in a two-site Down syndrome studyMinhas | Yang | Muschelli | Laymon | Zammit | Ellison | Johnson | Mathis | Crainiceanu | Klunk | Handen | Christian | Cohen | TudorascuTudorascu
28Visualizing brain astrocytes - characterization of 3H-BU99008 in human AD brain tissueLemoine | Malarte | Koistinen | NordbergLemoine
24Validation of highly sensitive and specific florbetaben positivity thresholds using ADNI participants and young controlsLandau | Korman | Bullich | De Santi | Stephens | Koeppe | JagustLandau
51Association Between [18F]NAV4694 PET Amyloid-β Measures and Fluid Biomarkers Across the Spectrum of Alzheimer DiseaseWang | Pascoal | Therriault | Benedet | Lussier | Savard | Kang | Tissot | Gauthier | Rosa-NetoWang
55Amyloid Load trajectories and chronicity reveal groups of early amyloid accumulators in Down syndromeZammit | Koscik | Laymon | Betthauser | Tudorascu | Cohen | Minhas | Johnson | Zaman | Mathis | Klunk | Handen | ChristianZammit
56Hippocampal-retrosplenial cortex connectivity predicts tau accumulation in cognitively normal older adultsZiontz | Adams | Baker | JagustZiontz
42Linking APOE ε4, blood-brain barrier dysfunction and inflammation to Alzheimer’s pathologyRiphagen | Ramakers | Freeze | Pagen | Hanseeuw | Verbeek | Verhey | JacobsRiphagen
9Preliminary evaluation of synaptic vesicle protein SV2A imaging with [11C]UCB-J across the cognitive spectrumDiFilippo | Murali | McKinney | Davenport | Barnhart | Engle | Betthauser | Johnson | Bendlin | ChristianDiFilippo
25Additive contribution of white matter hyperintensity to amyloid and neurodegeneration on cognitive decline in a diverse, community-based cohort of older adultsLao | Chesebro | Colon | Igwe | Gu | Schupf | Manly | Stern | Mayeux | BrickmanLao
6Age-related neural dedifferentiation of episodic memory networks is related to beta-amyloid and tau pathology in normal agingCassady | Adams | Maass | Harrison | Baker | JagustCassady
23Genetically informed quantitative Gradient Recalled Echo MRI reveals brain tissue in hippocampal subfields void of neurons in mild Alzheimer diseaseKothapalli | Benzinger | Aschenbrenner | Goyal | Fagan | Raichle | Morris | YablonskiyKothapalli
2Examining regional MK-6240 patterns and associations with amyloid and cognitive declineBetthauser | Cody | Koscik | Jonaitis | Erickson | Converse | Murali | Barnhart | Stone | Mueller | Clark | Asthana | Christian | JohnsonBetthauser
50Neuropsychiatric symptoms in cognitively impaired individuals are correlated with tau depositionTissot | Therriault | Pascoal | Chamoun | Lussier | Savard | Mathotaarachchi | L. Benedet | Thomas | Rosa-Neto | GauthierTissot
38Amyloid PET variability due to variation in MRI protocol and anatomical segmentationPalombit | Manber | Joules | WolzManber
48Monitoring disease pathophysiology using multiparametric PET acquisitions: The McGill TRIAD CohortStevenson | Chamoun | A. Pascoal | L. Benedet | Kang | Mathotaarachchi | Therriault | Thomas | Savard | Tissot | Lussier | Vinet-Celluci | Rahmouni | Gagné | Joung | Sbeiti | Shin | Vitali | Gauthier | Rosa-NetoStevenson
39The impact of automatic Tau PET processing on uptake variability and power analysis in ADPalombit | Manber | Joules | WolzManber
32PiB tracer delivery decreases overtime in preclinical AD – impact for amyloid pathology measurementMayblyum | Becker | Schultz | Farrell | Jacobs | Rubinstein | Sanchez | Thibault | Sperling | Price | Johnson | HanseeuwMayblyum
15CSF dynamics explains discrepant PET-CSF AD biomarkersGunter | Senjem | Cogswell | Schwarz | Lowe | Kantarci | Vemuri | Elder | Botha | Graff-Radford | Jones | Mielke | Graff-Radford | Knopman | Petersen | Jack, Jr.Gunter
45Development of a Qualitative Read Method for Characterizing the Presence and Extent of Brain Tau Deposition Using [18F]MK-6240 PET ImagingSeibyl | Salinas | Rajagovindan | Hutchison | Beaver | MartarelloSeibyl
26White matter hyperintensities are related to tau burden in late-Braak stage regionsLao | Laing | Igwe | Chesebro | Kreisl | Moreno | Luchsinger | BrickmanLao
44MCI patients demonstrate reliably increasing 18F-AV1451 PET uptake across three examsScott | Adamczuk | Gorman | Runkle | SuhyScott
37A clinically applicable proxy for gold standard quantification of amyloid-beta in Alzheimer’s disease: Bolus plus constant infusion 18F-AV45 PETOttoy | Kang | Verhaeghe | Stroobants | Bouhachi | Hsiao | Stevenson | Rahmouni | Chartrand | Massarweh | Soucy | Gauthier | Rosa-Neto | StaelensOttoy
13Beta-amyloid deposition and its association with metabolismGordon | Goyal | Couture | Flores | Morris | Raichle | Benzinger | VlassenkoGordon
19Data-Driven Biological Pattern Scoring of Flortaucipir Scans Outperforms ROIsJones | Graff-Radford | Botha | Senjem | Wiste | Josephs | Whitwell | Kantarci | Boeve | Petersen | Knopman | Lowe | JackJones
3Transcriptomic profiling of brain amyloidosis using peripheral blood-based gene expressionBharthur Sanjay | Svaldi | ApostolovaBharthur Sanjay
35Polygenic Risk for Cerebrospinal Fluid (CSF) Amyloid Predicts Brain Amyloid in Clinically Normal Older AdultsMoore | Dumitrescu | Schultz | Raghavan | Johnson | Mayeux | Sperling | Hohman | MorminoMoore
31Age prediction and amyloid deposition in SuperAgersMartersteck | Besson | Sridhar | Makowski-Woidan | Parrish | Katsaggelos | Mesulam | Bandt | RogalskiMartersteck
22Regional amyloid burden is associated with higher quantitative T1 in discrete hippocampal sub-regionsKohli | Yang | Vogt | Asthana | Betthauser | Alexander | Christian | Johnson | Kecskemeti | BendlinKohli
49Interaction between amyloid and neuroinflammation on apathy along the Alzheimer’s disease spectrumTissot | Kang | L. Benedet | Rahmouni | Pascoal | Chamoun | Therriault | Lussier | Savard | Mathotaarachchi | Thomas | Gauthier | Rosa-NetoTissot
41Associations between Neurogranin and imaging biomarkers of Alzheimer’s diseaseRahmouni | L.Benedet | Nicholas J. | Tissot | Pascoal | Kvartsberg | Chamoun | Kang | Lussier | Therriault | Stevenson | Savard | Mathotaarachchi | Thomas | Gauthier | Zetterberg | Blennow | Rosa-NetoRahmouni
43Heterogeneity of tau PET signal in the sub-nuclei of the amygdalaRubinstein | Jacobs | Augustinack | Properzi | Becker | Mayblyum | Thibault | Sanchez | Schultz | Hanseeuw | Gomez-Isla | Lois-Gomez | Price | Sperling | JohnsonRubinstein
18Retrospective prediction of amyloid accumulation trajectories in a risk-enriched Alzheimer’s disease cohort with sequential neural networkHwang | Koscik | Betthauser | Tao | Kim | Johnson | SinghHwang
16Predicting future amyloid spread with machine learning using longitudinal [C11]PiB-PET in preclinical Alzheimer's diseaseHao | Vogt | Meng | Hwang | Koscik | Betthauser | Christian | Johnson | Bendlin | SinghSingh
30Phantom-based harmonization of PET image reconstruction parameters between the Siemens ECAT HR+ PET and the GE Discovery MI PET/CT scannersLois | Grogg | El Fakri | Johnson | PriceLois
POSTER SESSIONS: 2A - Thursday, January 16 - 10:45 - 11:30 am; 2B - Thursday, January 16, 4:00 - 4:45 pm
BOARDTitleAuthor NamePresenter
100Entorhinal tau pathology is associated with medial temporal lobe hyperactivity in agingAdams | Maass | Berron | Harrison | Baker | Thomas | Stanfill | JagustAdams
80Sex differences in the rates of cognitive decline associated with temporal lobe FTP-PET signal: findings from the Harvard Aging Brain StudyBuckley | Properzi | Schultz | Jacobs | Kirn | Rentz | Hanseeuw | Johnson | SperlingBuckley
73Imaging synaptic and mitochondrial function in frontotemporal dementia using [11C]UCB-J, [18F]BCPP-EF and [11C]SA4503 PETClarke | Mansur | Passchier | Lewis | Evans | Chen | Schwarz | Takano | Gunn | Cash | Rabiner | RohrerClarke
105Longitudinal associations between lifestyle risk, β-amyloid, and cognition in late-midlifeCody | Koscik | Birdsill | Berman | Erickson | Chin | Clark | Christian | Betthauser | JohnsonCody
62Correlation of QSM signal with Alzheimer’s disease biomarkersCogswell | Wiste | Senjem | Therneau | Lowe | Knopman | Botha | Graff-Radford | Jones | Kantarci | Vemuri | Ferman | Boeve | Mielke | Schwarz | Gunter | Petersen | JackCogswell
71Quantitative regional amyloid burden and white matter changes in preclinical Alzheimer’s DiseaseCollij | Top | Stickney | Ingala | Tomassen | Lopes Alves | Yaqub | Wink | Van 't Ent | Scheltens | Van Berckel | Visser | Barkhof | Den Braber | AMYPAD consortiumCollij
70Individual variability in the cortical distribution of elevated 18F-AV1451 and 11C-PIB in a heterogeneous sample of AD patientsCollins | Eckbo | McGinnis | DickersonCollins
93Neuroinflammation in Alzheimer’s disease patients and correlates with amyloid and tau depositionEdison | Leng | Dani | BrooksEdison
85Sex differences in regional tau deposition in cognitively impaired patients with Alzheimer’s diseaseEdwards | La Joie | Iaccarino | Kim | Baker | Casaletto | Miller | Jagust | RabinoviciEdwards
69Higher microglia biomarker levels are associated with slower rates of amyloid-beta accumulation in humans and in a transgenic mouse model of amyloid-betaEwers | Brendel | Suarez-Calvet | Biechele | Sacher | Blume | Haass | FranzmeierEwers
99Early declines in learning and executive function associated with accumulating Aβ not tau in low PIB adultsFarrell | Papp | Buckley | Jacobs | Schultz | Properzi | Hanseeuw | Rentz | Johnson | SperlingFarrell
68Association of tau tangle burden with depressive symptoms in community dwelling older adults: a longitudinal studyGatchel | Marshall | Yang | Donovan | Buckley | Properzi | Quiroz | Rabin | Vannini | Amariglio | Chhatwal | Rentz | Blacker | Sperling | Johnson | HanseeuwGatchel
78Amyloid deposition affects the topography of cortical thinning in Lewy Body DiseaseYe | Touroutoglou | Brickhouse | Katz | Growdon | Johnson | Dickerson | GompertsGomperts
107Data-driven approach to characterization of tau accumulation in Braak staging groupsGroh | Svaldi | Stage | Sanjay | Risacher | Saykin | ApostolovaGroh
77A sensitive composite model to determine subtle cognitive differences in preclinical Alzheimer’s diseaseHahn | Kim | Kim | Jang | Kim | Na | Chin | SeoHahn
61Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the Memory Clinic: an F18-Flutemetamol amyloid-PET studyHanseeuw | Malotaux | Dricot | Quenon | Cerman | Buckley | Farrar | Ivanoiu | LhommelHanseeuw
92Amyloid deposition disrupts functional connectivity and graph properties within the Default Mode NetworkIngala | Wink | Prent | van 't Ent | Tomassen | ten Kate | Konijnenberg | Collij | Yaqub | Scheltens | de Goes | Teunissen | Barkhof | van Berckel | Visser | den Braberden Braber
74First-in-human evaluations of [11C]PS13 for imaging COX-1 and [11C]MC1 for imaging COX-2Kim | Juarez Anaya | Lee | Hong | Miller | Telu | Morse | Singh | Cortes-Salva | Henry | Ruiz-Perdomo | Montero Santamaria | Liow | Zoghbi | Fujita | Katz | Pike | InnisKim
91Prevalence of amyloid PET positivity in cognitively normal the East Asian populationsKim | Jung | Na | Kim | Won | SeoKim
64Evaluating the relationships among odor identification, tau pathology and neuroinflammation in Alzheimer’s diseaseKlein | Yan | Johnson | Tomljanovic | Zou | Polly | Honig | Brickman | Stern | Lee | KreislKlein
67Distinct effects of APOE ε2 on Aβ in Alzheimer- and Vascular-type cognitive impairmentLee | Lee | Park | Choe | Park | Cheon | Hahn | Ossenkoppele | Kim | Kim | Yoo | Jang | Cho | Kim | Kim | Jung | Park | DeCarli | Weiner | Yun | Na | SeoLee
79Longitudinal change in amyloid load over a 5-year period in cognitively healthy APOE4 carriers versus non-carriers: Effect of reference regionLuckett | Adamczuk | Schaeverbeke | Gabel | Van Laere | Dupont | VandenbergheLuckett
113Mild behavioral impairment is associated with tau pathology in cognitively impaired elderly individualsLussier | Pascoal | Therriault | Tissot | Savard | Benedet | Mathotaarachchi | Stevenson | Ismail | Rosa-Neto | GauthierLussier
114Modeling the trajectory of tau deposition in autosomal-dominant Alzheimer’s disease using the high-affinity tau tracer [18F]MK6240Lussier | Therriault | Pascoal | Savard | Mathotaarachchi | Robb | Stevenson | Gauthier | Rosa-NetoLussier
101Clinicopathological confirmation of 123I-FP-CIT SPECT (ioflupane) quantification methods in a spectrum of neurodegenerative syndromes and associated pathologiesMaltais | Jordan | Miyagawa | Lesnick | Przybelski | Min | Dickson | Murray | Kantarci | Boeve | LoweMaltais
106Exploring relationships between tau burden and naming in the aphasic variant of Alzheimer’s diseaseMartersteck | Sridhar | Coventry | Eldes | Wood | Kim | Mesulam | RogalskiMartersteck
65Elevated soluble phosphorylated tau is a marker of early amyloid PiB PET abnormalities and accumulationMcDade | Li | Joseph-Mathurin | Benzinger | Fagan | Xiong | Barthélemy | BatemanMcDade
112A clinically-relevant scheme for qualitatively rating tau PET, amyloid PET, and MRI in neurodegenerative cognitive presentationsMcGinnis | Collins | Eckbo | Brickhouse | DickersonMcGinnis
66Cerebrospinal fluid and PET measures of tau pathology may indicate different stages of AD pathological progressionMeyer | Pichet Binette | Gonneaud | Breitner | VilleneuveMeyer
96Use of the plasma amyloid-beta 42/40 ratio for predicting amyloid PET in a community-based populationMielke | Algeciras-Schimnich | Campbell | Syrjanen | Knopman | Jack Jr. | PetersonMielke
111Cerebrospinal fluid matrix metalloproteinases are associated with compromised white matter microstructure among older adults: the Vanderbilt memory & aging projectMoore | Pechman | Acosta | Bell | Anderson | Landman | Blennow | Zetterberg | Gifford | Hohman | JeffersonMoore
94Development of new alpha7 nicotinic receptor ASEM analogs for PET imagingNordberg | Lemoine | Mohan | Kuang | Nag | Jia | Miranda Azpiazu | Datta | Arakawa | Varnäs | Ågren | Långström | HalldinNordberg
108Associations between Alzheimer’s disease biomarkers and cognition among cognitively normal older adultsOh | Correia | SallowayOh
75[11C]MK-6884 PET tracer for M4 muscarinic cholinergic receptors in Alzheimer’s disease: comparison with [18F]FDG PETPascual | Zanotti-Fregonara | Yu | Funk | Arbones | Wang | Li | Cheng | Anderson | Hostetler | Basile | MasdeuPascual
81Amyloid and tau PET burden are associated with white matter bundle abnormalities in asymptomatic individuals at risk of Alzheimer’s diseasePichet Binette | Theaud | Gonneaud | Poirier | Descoteaux | VilleneuvePichet Binette
104Increased risk of Alzheimer’s disease in alcohol use disorder is not mediated by amyloid-beta in a middle-aged cross-sectional cohortRoyse | Himes | Minhas | Lopresti | Flanigan | NarendranRoyse
86Cross-sectional and longitudinal non-dichotomized CSF/PET Aβ data support existence of “CSF+ first” vs. “PET+ first” pathways of Aβ biomarkers changesSala | Nordberg | Rodriguez-VieitezSala
82NeuroToolkit CSF biomarkers track the progression of Alzheimer’s disease at very early stages and show that inflammatory markers modulate cerebral amyloid accumulationSalvadó | Molinuevo | Milà-Alomà | Blennow | Zetterberg | Operto | Falcón | Batrla | Battle | Buckley | Farrar | Minguillon | Fauria | Sánchez-Benavides | Suárez-Calvet | Gispert | the ALFA studySalvadó
83T1rho MRI measurement of amyloid plaque burden in cognitively unimpaired individuals: preliminary results in the ALFA+ cohortFalcón | Montesinos | Grau-Rivera | Suárez-Calvet | Puig-Pijoan | Cascales | Navalpotro-Gomez | Fernández-Lebrero | Sánchez-Valle | Gelpi | Sanfeliu | Rojas | Perissinotti | Niñerola-Baizán | Salvadó | Minguillon | Fauria | Molinuevo | Sánchez-González | Gispert | the ALFA studySalvadó
84Preliminary quantitative results of the AMYPAD prognostic and Natural History StudyGispert | Lopes-Alves | Gray | Buckley | Collij | Heeman | Salvadó | Scheltens | Frisoni | Ritchie | Vellas | Stephens | Ford | Molinuevo | Farrar | Barkhof | the AMYPAD ConsortiumSalvadó
72Effect of genetic risk, brain amyloid and hippocampal volume on normal variation in episodic memory performance in middle-aged and older adultsSchaeverbeke | Gabel | Adamczuk | Van Laere | Dupont | VandenbergheSchaeverbeke
103White matter disruption is an early and progressive feature of pre-symptomatic Dutch-type hereditary cerebral amyloid angiopathyScott | Schultz | Sohrabi | Gardener | Taddei | Bateman | Benzinger | Johnson | Sperling | Martins | Greenberg | Chhatwal | InvestigatorsScott
88Head-to-head comparison of F-Florbetaben and F-Flutemetamol uptakes in the cortex, striatum and white matterSeo | Cho | Moon | Choe | NaSeo
90PI-2620 Tau PET is associated with amyloid-beta levels in scans from subjects of the elenbecestat MissionAD programStephens | Bullich | Mueller | Berndt | De Santi | Scott | Adamczuk | Suhy | Kaplow | Giroux | Krause | Chang | AlbalaStephens
110Using famous faces to investigate the neural systems involved in name retrievalTennant | Jagust | La Joie | Adams | WinerTennant
109In vivo association of mitochondrial dysfunction with tau pathology in early Alzheimer’s diseaseTerada | Therriault | Min Su | Savard | Ouchi | Rosa-NetoTerada
102Preliminary results: PiB and MK6240 regional PET measures associated with digitized clock drawing performanceMayblyum | Thibault | Moody | Farrell | Jiang | Jacobs | Rubinstein | Sanchez | Katz | Sperling | Papp | Rentz | JohnsonThibault
97Associations between longitudinal cognitive measures and cross-sectional tau in adults with Down syndromeTudorascu | Comer | Zammit | Laymon | Minhas | Ellison | Zaman | Ances | Johnson | Mathis | Klunk | Christian | Handen | Hartley | CohenTudorascu
60Longitudinal flortaucipir ([18F]AV-1451) PET uptake in Semantic DementiaUtianski | Whitwell | Martin | Botha | Schwarz | Duffy | Clark | Spychalla | Senjem | Petersen | Knopman | Jack, Jr. | Lowe | JosephsUtianski
76Assessing Aβ, tau, and reactive astrocytosis in aging and ADVillemagne | Harada | Doré | Furumoto | Mulligan | Kudo | Krishnadas | Huang | Yanai | Rowe | OkamuraVillemagne
63Developing a novel alpha-synuclein (a-syn) positron emission tomography (PET) tracer for the diagnosis of Parkinson’s disease (PD) and other a-synucleinopathiesVokali | Molette | Tsika | Ravache | Rodriguez | Jürgens | Melo dos Santos | Sandiego | Russell | Gunn | Darmency | Piorkowska | Poli | Kroth | Capotosti | Hliva | Sol | Marek | Stöhr | Lowe | Pfeifer | Kosco-VilboisVokali
95Biological underpinnings of typical and atypical Alzheimer’s dementia phenotypesWhitwell | Tosakulwong | Graff-Radford | Weigand | Schwarz | Senjem | Ertekin-Taner | Jones | Boeve | Knopman | Jack | Petersen | Lowe | JosephsWhitwell
89Sleep impairment predicts longitudinal accumulation of β-amyloidWiner | Mander | Jagust | WalkerWiner
87Personality and amyloid accumulation in cognitively normal agingYoon | Baker | Korman | Tennant | Harrison | JagustYoon
98Associations of amyloid deposition and FDG uptake in aging and cognitively impaired elders with and without moderate to severe periventricular white matter hyperintensitiesZukotynski | Gaudet | Kuo | Adamo | Goubran | Scott | Bocti | Borrie | Chertkow | Frayne | Hsiung | Laforce | Noseworthy | Prato | Sahlas | Smith | Sossi | Thiel | Soucy | Tardif | BlackZukotynski
POSTER SESSIONS: 3A - Friday, January 17, 9:15 - 10:00 am; 3B - Friday, January 17, 3:15 - 4:00 pm
BOARDTitleAuthor NamePresenter
132CSF P-tau detects cerebral tau accumulation earlier than tau PET in amyloid positive elderly adultsGuo | Jagust | LandauGuo
162Association between cerebrospinal fluid neurofilament light chain and markers of neurofibrillary pathophysiology: Findings from the Knight Alzheimer Disease Research CenterSchultz | Schindler | Chen | Sutphen | Morris | Fagan | Gordon | BenzingerSchultz
130Functional connectivity brain architecture predicts the rate of tau accumulation in Alzheimer’s diseaseFranzmeier | Neitzel | Rubinski | Smith | Strandberg | Ossenkoppele | Hansson | EwersFranzmeier
154Widespread amyloid is necessary to detect tau-PET signal beyond the entorhinal cortex and cognitive declineOzlen | Binette | Köbe | Meyer | VilleneuveOzlen
135Preclinical characterization of [18F]THK-5562, a novel tau PET tracer with little off-target bindingHarada | Lerdsirisuk | Yiqing | Ezura | Shimizu | Morito | Arai | Yanai | Kudo | Furumoto | OkamuraHarada
155Using 18F-Flortaucipir visual assessment to define T-status in the AT(N) framework: evaluation of intra- and inter-rater reliabilityProvost | Iaccarino | Soleimani-Meigooni | Lesman-Segev | La Joie | Edwards | Strom | Pham | Mellinger | Janabi | Baker | Jagust | RabinoviciProvost
156Defining T-status in the AT(N) framework: comparison of 18F-Flortaucipir visual assessment, SUVR quantification and CSF pTauProvost | Iaccarino | Soleimani-Meigooni | Lesman-Segev | La Joie | Mattsson | Hansson | Eichenlaub | Edwards | Strom | Pham | Mellinger | Janabi | Baker | Jagust | RabinoviciProvost
133Amyloid, tau, and atrophy in preclinical Alzheimer’s disease: a longitudinal studyHanseeuw | Jacobs | Schultz | Buckley | Properzi | Farrell | Scott | Hampton | Sanchez | Sperling | JohnsonHanseeuw
126Quantifying tau PET imaging reliably in the presence of off-target bindingChen | Gordon | McCullough | Zaza | Mejias | Dincer | Flores | Keefe | Paulick | Jackson | Koudelis | Su | Morris | BenzingerChen
157Plasma neurofilament light is associated with regional tau tangle burden in autosomal dominant Alzheimer's disease: findings from the COLBOS ProjectQuiroz | Zetterberg | Reiman | Sanchez | Guzman-Velez | Fox-Fuller | Arboleda-Velasquez | Baena | Gatchel | Sperling | Johnson | Blennow | LoperaQuiroz
159Measuring increases of tau pathology in Alzheimer's disease using [18F]GTP1 (Genentech tau probe 1) PET imagingSanabria Bohorquez | Baker | Manser | Toth | Teng | Marik | WeimerSanabria Bohorquez
131How innocent is PART? Mesial temporal tau is associated with worse cognitive performance in Aβ-negative cognitively normal individualsGrootGroot
137In vivo amyloid-PET and tau-PET evidence in early-onset Alzheimer’s Disease: taking the LEADSIaccarino | La Joie | Lesman-Segev | Soleimani-Meigooni | Provost | Collins | Aisen | Borowski | Eloyan | Fagan | Foroud | Gatsonis | Jack Jr. | Kramer | Saykin | Toga | Vemuri | Day | Graff-Radford | Honig | Jones | Masdeu | Mendez | Onyike | Rogalski | Salloway | Wolk | Wingo | Koeppe | Dickerson | Apostolova | Carrillo | RabinoviciIaccarino
174Associations of tau pathology and functional connectivity with retrospective cognitive change among cognitively normal older adultsShafer | Bilgel | Ziontz | Wong | ResnickZiontz
158Application of tau PET as a biomarker of Alzheimer’s disease in therapeutic trials: a pharmaceutical industry perspectiveSalinas | Lohith | Guo | Wooten | Tulip | Sanjeewa | Comley | Sur | Hostetler | Beaver | MartarelloSalinas
167Intrinsic connectivity of the human brain provides scaffold for tau aggregation in Alzheimer's diseaseTherriault | Pascoal | Savard | Mathotaarachchi | Benedet | Chamoun | Gauthier | Saha-Chaudhuri | Massarweh | Rosa-NetoTherriault
138Multimodal in vivo investigation of amyloid and tau biomarkers associations with cerebrospinal fluid NfL and YKL40 levelsIaccarino | La Joie | Edwards | Lesman-Segev | Strom | Pham | Chaudhary | Fenton | Jerome | Janabi | Baker | Miller | Jagust | Fagan | RabinoviciIaccarino
122Perfusion-phase 18F-PI-2620 tau-PET imaging as a surrogate marker of neuronal injuryBrendel | Beyer | Nitschmann | Barthel | van Eimeren | Marek | Song | Palleis | Respondek | Sauerbeck | Hammes | Barbe | Onur | Jessen | Saur | Schroeter | Rumpf | Rullmann | Schildan | Patt | Neumaier | Barret | Madonia | Russel | Stephens | Roeber | Herms | Bötzel | Levin | Classen | Hoeglinger | Bartenstein | Villemagne | Drzezga | Seibyl | SabriBrendel
123Binding characteristics of 18F-PI-2620 differentiate the clinically predicted tau isoform in suspected 3/4-repeat and 4-repeat tauopathiesBrendel | Song | Beyer | Barthel | van Eimeren | Marek | Palleis | Kaiser | Respondek | Sauerbeck | Hammes | Barbe | Onur | Jessen | Saur | Schroeter | Rumpf | Rullmann | Schildan | Patt | Neumaier | Barret | Madonia | Russel | Stephens | Roeber | Herms | Bötzel | Levin | Classen | Hoeglinger | Bartenstein | Villemagne | Drzezga | Seibyl | SabriBrendel
12418F-PI2620 tau-PET for assessment of heterogeneous neuropathology in corticobasal syndromeBrendel | Palleis | Prix | Gehmeyr | Bötzel | Danek | Höllerhage | Sauerbeck | Beyer | Nitschmann | Song | Stephens | Barthel | Patt | Sabri | Drzezga | van Eimeren | Villemagne | Bartenstein | Perneczky | Haass | Levin | HoeglingerBrendel
173[18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s diseaseWolters | Ossenkoppele | Verfaillie | Coomans | Timmers | Visser | Tuncel | Golla | Windhorst | Boellaard | van der Flier | Teunissen | Scheltens | van BerckelWolters
170Hippocampal tau accumulation predicts individual differences in episodic memory in cognitively normal older adultsTrelle | Toueg | Castillo | Channappa | Corso | Hunt | Jayakumar | Nadiadwala | Guo | Azevedo | Shin | Davidson | Deutsch | Hall | Sha | Fredericks | Kerchner | Carr | Chin | Wagner | MorminoTrelle
128Comparison of quantitative cutoff methods for [18F]AV-1451Minhas | Laymon | Lopresti | Snitz | Tudorascu | Aizenstein | Lopez | Mathis | Klunk | CohenCohen
134Increased levels and phosphorylation of soluble tau proteins occur earlier than changes in Tau PET in Alzheimer’s diseaseHansson | Andersson | Janelidze | Ossenkoppele | Insel | Strandberg | Zetterberg | Blennow | Chai | Dage | Stomrud | Smith | Palmqvist | MattssonHansson
172Temporal evaluation for maximum CSF pTau181 – [18F]Flortaucipir concordanceWisch | Gordon | Schindler | Flores | Dincer | Fagan | Benzinger | Morris | AncesAnces
121Local associations between tau and neurodegeneration among non-demented older adultsBilgel | Wong | ResnickBilgel
150Entorhinal cortical tau accumulation is inversely associated with hippocampal synaptic density in older individuals with normal cognition and early Alzheimer’s diseaseMecca | Chen | Naganawa | Toyonaga | Godek | Harris | Bartlett | Zhao | Gallezot | Nabulsi | Huang | Arnsten | Carson | van DyckMecca
142Comparison of longitudinal change metrics for 18F-RO948 PET among cognitively unimpaired and patients with MCI or AD dementia in the BioFINDER2 studyKlein | Sanabria | Leuzy | Borroni | Mattsson | Palmqvist | Stomrud | Smith | HanssonKlein
171Temporo-limbic tau burden, as measured by 18F-AV1451, is a correlate of hippocampal volume loss over timeFischer | Ahnen | Dissertori | Lustermann | Weber | Buck | Kagerer | Gietl | Hock | UnschuldUnschuld
127[18F]THK5317 imaging as a predictive tool of prospective cognitive decline in prodromal and dementia-stage Alzheimer’s diseaseChiotis | Savitcheva | Poulakis | Saint-Aubert | Wall | Antoni | NordbergChiotis
143Validation of clinical protocols for clinicians analyzing 18F-PI-2620 tau PET/MRI imagesKoran | Shams | Adams | Cazevedo | Toueg | Corso | Hunt | Castillo | Hall | Sha | Fredericks | Greicius | Wagner | Zaharchuk | Davidzon | Chin | MorminoMormino
147A comparison of ischemic stroke-induced changes on 18F-APN-1607 (18F-PMPBB3) and 18F-THK-5351 uptake patternsLin | Hsiao | Huang | HuangLin
161Clinical evaluation o[18F]-JNJ-64326067, a candidate PET tracer for the detection of tau pathology in Alzheimer’s diseaseSchmidt | Janssens | Moechars | Rombouts | Timmers | Barret | Constantinescu | Madonia | Russell | Sandiego | KolbSchmidt
141Prediction of brain tau accumulation in amyloid positive cognitive impairment patients using multimodal biomarkers with machine learning approachKim | Park | Park | Kang | Kim | Jang | Kim | Na | Lee | SeoKim
125Optimal reference region for the quantification of tau load in the brain using 18F-PI-2620 PETBullich | Müller | Roé-Vellvé | Jovalekic | Perrotin | De Santi | Koglin | StephensBullich Roig
153Factors predicting tau PET status in cognitively unimpaired and impaired individualsOssenkoppele | Leuzy | Cho | La Joie | Strandberg | Matsson | Palmqvist | Lyoo | Rabinovici | Smith | HanssonOssenkoppele
164The rate of accumulation of tau aggregates is higher in females and younger individualsSmith | Mattsson | Pontecorvo | Devous | Strandberg | Ossenkoppele | HanssonSmith
120Depression is predicted by tau imaging biomarker among cognitively normal adultsBabulal | Roe | Stout | Rajasekar | Wisch | Benzinger | Morris | AncesAnces
169Elevated medial temporal lobe Tau PET with 18F-PI2620 in normal controls with “borderline” neuropsychological testing profilesToueg | Deutsch | Castillo | Hunt | Corso | Trelle | Harrison | Azevedo | Shen | Anders | Hall | Fredericks | Sha | Davidzon | Chin | Khalighi | Wagner | MorminoToueg
14918F-APN-1607: a promising PET tracer for multiple tauopathiesMargolin | Lin | Tempest | Chen | Marek | Russell | Sandiego | Huang | Hsiao | Tamagnan | Alagille | Guan | Lu | Zuo | Higuchi | JangMargolin
148Longitudinal change in [18F]GTP1 SUVR over 18 months depends on baseline SUVR intensity and spatial distribution and shows trends with cognitive declineManser | Sanabria Bohorquez | Teng | Baker | Toth | Marik | WeimerManser
168Changes in volumetric MRI measures at 12 months significantly correlate with baseline [18F]GTP1 SUVR, but not [18F]GTP1 changeToth | Sanabria Bohorquez | Manser | Baker | Teng | Marik | WeimerToth
16318F-PM-PBB3 (18F-APN-1607) uptake associates with plasma NfL level and motor disability in patients with progressive supranuclear palsyShimada | Tagai | Tatebe | Matsuoka | Kubota | Takahata | Takado | Shinotoh | Yamamoto | Sano | Seki | Nakano | Ono | Hirano | Tempest | Jang | Sahara | Kawamura | Zhang | Tokuda | HiguchiShimada
136Comparison of tau PET imaging using 18F-APN-1607 and 18F-THK5351 in Alzheimer's disease patients and normal controlsHsiao | Lin | Huang | HuangHsiao
145Diagnostic performance of [18F]RO948 tau positron emission tomography in the differentiation of AD from other neurodegenerative disordersLeuzy | Smith | Ossenkoppele | Santillo | Borroni | Klein | Olsson | Jögi | Palmqvist | Mattsson | Strandberg | Stomrud | HanssonLeuzy
146Longitudinal changes in tau pathology measured by [18F]RO948 tau-PET are associated with elevated CSF P-tau: Preliminary findings from the Swedish BioFINDER-2 studyLeuzy | Klein | Ossenkoppele | Mattsson | Janelidze | Palmqvist | Strandberg | Coloma | Borroni | Stomrud | Smith | HanssonLeuzy
166Tau positivity: comparing flortaucipir meta-ROI vs maximal single regionTherneau | Schwarz | Wiste | Gunter | Senjem | Lowe | Kantarci | Petersen | Knopman | Mielke | Jones | JackTherneau
165Resting state functional connectivity associations with F18-Florbetapir PET versus F18-Flortaucipir PETSvaldi | Goñi | Stage | Abbas | Dzemidzic | West | Risacher | Saykin | ApostolovaSvaldi
139Activated microglia and amyloid load potentiate tau deposition leading to cognitive dysfunction in Alzheimer’s diseaseKang | Ottoy | Savard | Pascoal | Mathotaarachchi | Benedet | Chamoun | Therriault | Lussier | Tissot | Thomas | Stevenson | Rahmouni | Arias | Wang | Massarweh | Soucy | Gauthier | Rosa-NetoKang
140Tauopathy in females is more vulnerable to amyloid or neuroinflammation in Alzheimer’s diseaseKang | Ottoy | Chamoun | Mathotaarachchi | Savard | Benedet | Pascoal | Therriault | Lussier | Tissot | Thomas | Stevenson | Rahmouni | Fernandez-Arias | Wang | Massarweh | Soucy | Gauthier | Rosa-NetoKang
152In vivo uptake of 18F-PM-PBB3 (18F-APN-1607) in patients with corticobasal syndromeNakano | Shimada | Tagai | Matsuoka | Kubota | Takahata | Takado | Shinotoh | Yamamoto | Sano | Seki | Hirano | Ono | Tempest | Jang | Sahara | Kawamura | Zhang | Kuwabara | HiguchiNakano
144Cerebrospinal fluid tau phosphorylated at amino acid 181 or 231: a biomarker comparison in the detection of neurofibrillary tangle pathology in the Alzheimer’s disease spectrumBenedet | Ashton | Pascoal | Stoops | Francois | Vanmechelen | Karikari | Mathotaarachchi | Savard | Therriault | Chamoun | Zetterberg | Blennow | Rosa-NetoBenedet
151Mental and physical activity during the uptake period affects off-target binding in extra- and within-brain Tau PET (18F-FTP)Min | Apgar | Scott | Hol | Lundt | Albertson | Schwarz | Botha | Vemuri | Gunter | Petersen | Jack | LoweMin
160Evaluation of tau PET staging in the A4/LEARN StudySanchez | Becker | Jacobs | Hanseeuw | Mayblyum | Rubinstein | Thibault | Schultz | Seshadri | Quiroz | Rentz | Price | Sperling | Johnson | the A4 Study TeamSanchez
129Pilot study on the relationship between 18F-MK-6240 and VBM in early and late stages of ADFernandez Arias | Pascoal | Benedet | Thierrault | Su Kang | Savard | Ottoy | Mathotaarachchi | Lussier | Tissot | Thomas | Stevenson | Rahmouni | Wang | Massarweh | Soucy | Gauthier | Rosa-NetoFernandez Arias

HAI Past Poster Sessions